bcbs fep glp 1 coverage 2025 GLP-1 for obesity treatment in 13 US states' Medicaid programs bcbs fep glp 1 coverage

Jiao Y, Chen X, Liu L, Lu Y, Gao M, Wang Q, et al

Benchmarks from the sources above can serve as comparison points

GLP-1 Weight Loss for Insulin Resistance and Metabolic Health Many patients interested in GLP-1 therapy also struggle with insulin resistance, prediabetes, type 2 diabetes risk, abdominal weight gain, cravings, fatigue after meals, or difficulty losing weight despite eating less

The primary advantages of GLP-1RAs lie in glucose reduction, cardiorenal benefits, and amelioration of metabolic syndrome, all of which are substantiated by a plethora of evidence-based studies [1,2,3,4]

T2DM is the most common endocrine disorder, characterised by insulin resistance and impaired insulin secretion, and it is one of the fastest growing non-communicable diseases in the world (Reference Shaw, Sicree and Zimmet9)

[DOI] [PubMed] [Google Scholar] 8.Piva S.R., Susko A.M., Khoja S.S., Josbeno D.A., Fitzgerald G.K., Toledo F.G.S